Nektar Therapeutics (NASDAQ: NKTR) is a Healthcare company (Biotechnology) with a market capitalization of $1.0B. The Maz Rating grades it against the other companies in its sector.
Nektar Therapeutics's current Maz Rating and its five factor grades are for members: log in to see them.
At $35.91, Nektar Therapeutics trades at 19.9x sales and 1.5x book value. Over the last twelve months it generated about $52M of revenue and a net loss of $184M. It runs a gross margin of 99.7%, an operating margin of -301.8% and a net margin of -339.7%. It shows return on equity of -29.3%, return on invested capital of -16.0% and a free cash flow yield of -25.0%. On the balance sheet: a debt-to-equity ratio of 0.09 and a current ratio of 9.00. Over the past 52 weeks the share price ranged from $33.40 to $109.00, with a beta of 1.15.
Nektar Therapeutics does not currently pay a dividend.
33 Wall Street analyst ratings cover the stock: 22 Buy, 6 Hold and 5 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.